Fundraising FoxUrotronic
Plymouth, US · Founded 2014 · Delaware corporation · 11 known investors
Find your way into Urotronic
Urotronic develops drug-coated balloons for interventional urology, including the Optilume products for treating benign prostatic hyperplasia (BPH) and urethral strictures. Its devices are marketed to physicians and patients in the urology field.
Founders & leadership
Investors · 11
How we know: HM Venture Partners's portfolio page · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: funding news · hitconsultant.net · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: press coverage · Not right? Tell us
Also in the syndicate · 3
Reported raises · per SEC filings
Form D private placements$38.5M disclosed across 3 rounds · 2018–2020
▶$12.4MraisedOct 2020 · 26 investors · Other Health CareRule 506(b)
- Jeff ThomasDirector
- Rushu LuoDirector
- Doug KohrsDirector
- Junfeng WangDirector
- Yuriy PrilutskiyDirector
- Lixiao WangDirector, Promoter
- Hui HuDirector, Promoter
- David PerryExecutive Officer, Director
- Tan ChingDirector
- Offering amount
- $19.9M
- Amount sold
- $12.4M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20MraisedAug 2018 · 7 investors · Other Health CareRule 506(b)
- Junfeng WangDirector
- Doug KohrsDirector
- Tan ChingDirector
- David PerryExecutive Officer, Director
- Lixiao WangDirector, Promoter
- Hui HuDirector, Promoter
- Rushu LuoDirector
- Offering amount
- $20M
- Amount sold
- $20M
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$6.1MraisedJul 2018 · 21 investors · Other Health CareRule 506(b)
- Junfeng WangDirector
- David PerryExecutive Officer, Director
- Tan ChingDirector
- Hui HuDirector, Promoter
- Lixiao WangDirector, Promoter
- Doug KohrsDirector
- Offering amount
- $6.1M
- Amount sold
- $6.1M
- Proceeds to insiders
- $285.5K
- First sale
- Mar 2018
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlap
Companies competing with Urotronic for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Urotronic do?
- Urotronic develops drug-coated balloons for interventional urology, including the Optilume products for treating benign prostatic hyperplasia (BPH) and urethral strictures. Its devices are marketed to physicians and patients in the urology field.
- Who are Urotronic's investors?
- Urotronic's investors include HM Venture Partners, Enterprise Ireland, Gilde Healthcare, Ireland Strategic Investment Fund, Legend Capital, Lightstone Ventures, MVM Life Science Partners, OrbiMed.
- How much funding has Urotronic raised?
- Urotronic has disclosed $38.5M raised across 3 rounds.
- Where is Urotronic headquartered?
- Urotronic is headquartered in Plymouth, US.